Skip to main content
Premium Trial:

Request an Annual Quote

PCR Firm QuantaLife Raises $17.2M in Series B

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PCR technology development company QuantaLife announced late Friday that it had closed on a Series B financing round, raising $17.2 million.

The majority of the funds will be used to create a commercialization operation to launch its Droplet Digital PCR platform for the research market and to accelerate development of targeted diagnostic tests, the Pleasanton, Calif.-based company said in a statement.

QuantaLife's system was unveiled last month GenomeWeb Daily News' sister publication PCR Insider reported. The system has been available to early-access users, but the company has made it available to interested parties at a price of $50,000. The Droplet Digital PCR system, which comprises a droplet generator and a droplet reader, uses microfluidics and emulsion chemistry.

The Series B round was led by existing investors including Paladin Capital Group. New investors Merieux Developpement and Vital Financial also participated, QuantaLife said.

"With the completion of this financing, we have diversified our world-class investor base and we are well-positioned for a successful transition to commercialization," QuantaLife Founder and CEO Bill Colston said.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.